Metastatic melanomas express inhibitory low affinity Fc gamma receptor and escape humoral immunity

Dermatology Research and Practice

Volumn 2010, Issue 1, 2010, Pages

  Cohen Solal, Joel F G ^a,b   Cassard, Lydie ^a,c   Fournier, Emilie M ^a,d   Loncar, Shannon M ^b   Fridman, Wolf Herman ^a   Sautès Fridman, Catherine ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UMRS 872 Universite Pierre et Marie Curie ^*  (United States)

^c INSTITUT PASTEUR   (France)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953298663     PISSN: None     EISSN: 16876113     Source Type: Journal    
DOI: 10.1155/2010/657406     Document Type: Review

References (95)

1. Kaas Q., Ehrenmann F., Lefranc M.-P., IG, TR and IgSF, MHC and MhcSF: what do we learn from the IMGT Colliers de Perles? Briefings in Functional Genomics and Proteomics 2007 6 4 253 264 2-s2.0-46049112076 10.1093/bfgp/elm032 (Pubitemid 351894484)
2. Brümmendorf T., Rathjen F. G., Cell adhesion molecules 1: immunoglobulin superfamily. Protein Profile 1995 2 9 963 1108 2-s2.0-0029443827
3. Halaby D. M., Mornon J. P. E., The immunoglobulin superfamily: an insight on its tissular, species, and functional diversity. Journal of Molecular Evolution 1998 46 4 389 400 2-s2.0-0031979387 10.1007/PL00006318 (Pubitemid 28164943)
4. Qiu W. Q., de Bruin D., Brownstein B. H., Pearse R., Ravetch J. V., Organization of the human and mouse low-affinity Fc γ R genes: duplication and recombination. Science 1990 248 4956 732 735 2-s2.0-0025340989
5. Reth M., Antigen receptor tail clue. Nature 1989 338 6214 383 384 2-s2.0-0024980981
6. Cambier J. C., Antigen and Fc receptor signaling the awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). Journal of Immunology 1995 155 7 3281 3285 2-s2.0-0029082078
7. Amigorena S., Bonnerot C., Drake J. R., Cytoplasmic domain heterogeneity and functions of IgG Fc receptor in B lymphocytes. Science 1992 256 5065 1808 1812 2-s2.0-0026769620
8. Daëron M., Latour S., Malbec O., The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc γ RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995 3 5 635 646 2-s2.0-0028851582
9. Kinet J.-P., Launay P., Fc α / R: single member or first born in the family? Nature Immunology 2000 1 5 371 372 2-s2.0-0034332074
10. Fridman W. H., Bonnerot C., Daeron M., Amigorena S., Teillaud J.-L., Sautes C., Structural bases of Fc γ receptor functions. Immunological Reviews 1992 125 49 76 2-s2.0-0026611219
11. Hulett M. D., Hogarth P. M., Molecular basis of Fc receptor function. Advances in Immunology 1994 57 1 127 2-s2.0-0028672732
12. Ravetch J. V., Bolland S., IgG Fc receptors. Annual Review of Immunology 2001 19 275 290 2-s2.0-0035057022 10.1146/annurev.immunol.19.1.275 (Pubitemid 32368037)
13. Cohen-Solal J. F., Cassard L., Fridman W.-H., Sautès-Fridman C., Fc γ receptors. Immunology Letters 2004 92 3 199 205 2-s2.0-1842815081 10.1016/j.imlet.2004.01.012 (Pubitemid 38471958)
14. Nimmerjahn F., Ravetch J. V., Analyzing antibody-Fc-receptor interactions. Methods in Molecular Biology 2008 415 151 162 2-s2.0-45549101222
15. Fournier E. M., Sibéril S., Costes A., Activation of human peripheral IgM+ B cells is transiently inhibited by BCR-independent aggregation of Fc gammaRIIB. Journal of Immunology 2008 181 8 5350 5359 2-s2.0-54049146662
16. Pearse R. N., Kawabe T., Bolland S., Guinamard R., Kurosaki T., Ravetch J. V., SHIP recruitment attenuates Fc γ RIIB-induced B cell apoptosis. Immunity 1999 10 6 753 760 2-s2.0-0033151596 10.1016/S1074-7613(00)80074-6 (Pubitemid 29302928)
17. Tzeng S.-J., Bolland S., Inabe K., Kurosaki T., Pierce S. K., The B cell inhibitory Fc receptor triggers apoptosis by a novel c-Abl family kinase-dependent pathway. Journal of Biological Chemistry 2005 280 42 35247 35254 2-s2.0-27444446355 10.1074/jbc.M505308200 (Pubitemid 41532712)
18. Xiang Z., Cutler A. J., Brownlie R. J., Fc γ Rllb controls bone marrow plasma cell persistence and apoptosis. Nature Immunology 2007 8 4 419 429 2-s2.0-33947575824 10.1038/ni1440 (Pubitemid 46745417)
19. Sahin U., Türeci Ö., Schmitt H., Human neoplasms elicit multiple specific immune responses in the autologous host. Proceedings of the National Academy of Sciences of the United States of America 1995 92 25 11810 11813 2-s2.0-13344282077 10.1073/pnas.92.25.11810 (Pubitemid 26014201)
20. Jäger E., Chen Y.-T., Drijfhout J. W., Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. Journal of Experimental Medicine 1998 187 2 265 270 2-s2.0-2642683198 10.1084/jem.187.2.265 (Pubitemid 28060443)
21. Lake D. F., Huynh W. C., Hersh E. M., Natural and induced human antibody response to cancer. Cancer Investigation 2000 18 5 480 489 2-s2.0-0034119422 (Pubitemid 30337528)
22. Ragupathi G., Meyers M., Adluri S., Howard L., Musselli C., Livingston P. O., Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. International Journal of Cancer 2000 85 5 659 666 2-s2.0-0033950463 10.1002/(SICI)1097-0215(20000301)85:5<659::AID-IJC11>3.0.CO;2-5 (Pubitemid 30080479)
23. Lutzky J., Gonzalez-Angulo A. M., Orzano J. A., Antibody-based vaccines for the treatment of melanoma. Seminars in Oncology 2002 29 5 462 470 2-s2.0-0037010049 10.1053/sonc.2002.35241 (Pubitemid 35178285)
24. Ehlken H., Schadendorf D., Eichmüller S., Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells. International Journal of Cancer 2004 108 2 307 313 2-s2.0-0346752002 10.1002/ijc.11537 (Pubitemid 37541788)
25. White C. A., Berlfein J. R., Grillo-López A. J., Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphoma. Current Pharmaceutical Biotechnology 2000 1 4 303 312 2-s2.0-0034570689
26. Carter P. J., Potent antibody therapeutics by design. Nature Reviews Immunology 2006 6 5 343 357 2-s2.0-33646352962 10.1038/nri1837
27. Akiyama K., Ebihara S., Yada A., Targeting apoptotic tumor cells to Fc γ R provides efficient and versatile vaccination against tumors by dendritic cells. Journal of Immunology 2003 170 4 1641 1648 2-s2.0-0037442125 (Pubitemid 36197377)
28. Rafiq K., Bergtold A., Clynes R., Immune complex-mediated antigen presentation induces tumor immunity. Journal of Clinical Investigation 2002 110 1 71 79 2-s2.0-0036307752 10.1172/JCI200215640 (Pubitemid 34743467)
29. Adams D. O., Hall T., Steplewski Z., Koprowski H., Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proceedings of the National Academy of Sciences of the United States of America 1984 81 11 I 3506 3510 2-s2.0-0021235584 (Pubitemid 14122703)
30. Denkers E. Y., Badger C. C., Ledbetter J. A., Bernstein I. D., Influence of antibody isotype on passive serotherapy of lymphoma. Journal of Immunology 1985 135 3 2183 2186 2-s2.0-0022340434 (Pubitemid 16240056)
31. Maloney D. G., Liles T. M., Czerwinski D. K., Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994 84 8 2457 2466 2-s2.0-0028127304 (Pubitemid 24317376)
32. Dyer M. J. S., Hale G., Hayhoe F. G. J., Waldmann H., Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989 73 6 1431 1439 2-s2.0-0024566393 (Pubitemid 19131883)
33. Clynes R., Takechi Y., Moroi Y., Houghton A., Ravetch J. V., Fc receptors are required in passive and active immunity to melanoma. Proceedings of the National Academy of Sciences of the United States of America 1998 95 2 652 656 2-s2.0-0031905710 10.1073/pnas.95.2.652 (Pubitemid 28083798)
34. Bevaart L., Jansen M. J. H., van Vugt M. J., Sjef Verbeek J., van de Winkel J. G. J., Leusen J. H. W., The high-affinity IgG receptor, Fc γ RI, plays a central role in antibody therapy of experimental melanoma. Cancer Research 2006 66 3 1261 1264 2-s2.0-32944454324 10.1158/0008-5472.CAN-05-2856 (Pubitemid 43259901)
35. Nimmerjahn F., Bruhns P., Horiuchi K., Ravetch J. V., Fc γ RIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005 23 1 41 51 2-s2.0-22544487815 10.1016/j.immuni.2005.05.010 (Pubitemid 41019656)
36. Nimmerjahn F., Ravetch J. V., Fc γ receptors: old friends and new family members. Immunity 2006 24 1 19 28 2-s2.0-30444461383 10.1016/j.immuni. 2005.11.010 (Pubitemid 43077197)
37. Otten M. A., van der Bij G. J., Verbeek S. J., Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. Journal of Immunology 2008 181 10 6829 6836 2-s2.0-58149198794
38. Clynes R. A., Towers T. L., Presta L. G., Ravetch J. V., Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Medicine 2000 6 4 443 446 2-s2.0-0034076307 10.1038/74704 (Pubitemid 30208162)
39. Van Spriel A. B., van Ojik H. H., Bakker A., Jansen M. J. H., van de Winkel J. G. J., Mac-1 (CD11b/CD18) is crucial for effective fc receptor-mediated immunity to melanoma. Blood 2003 101 1 253 258 2-s2.0-0037217937 10.1182/blood.V101.1.253 (Pubitemid 36025915)
40. Muretto P., pietro.muretto@virgilio.it Immunohistochemical study of dendritic cells in foetal skin and lymph-nodes supporting the hypothesis for the neural crest origin of Langerhans cells. Italian Journal of Anatomy and Embryology 2008 113 4 237 247 2-s2.0-0019231840
41. Muretto P., The relationship of langerhans cells to melanocytes and schwann cells in mature cystic teratomas of the ovary. International Journal of Surgical Pathology 2007 15 3 266 271 2-s2.0-34250880892 10.1177/1066896907302227 (Pubitemid 46976541)
42. Schmitt D. A., Hanau D., Bieber T., Human epidermal Langerhans cells express only the 40-kilodalton Fc γ receptor (FcRII). Journal of Immunology 1990 144 11 4284 4890 2-s2.0-0025282253 (Pubitemid 20187770)
43. Vedeler C. A., Matre R., Kristoffersen E. K., Ulvestad E., IgG Fc receptor heterogeneity in human peripheral nerves. Acta Neurologica Scandinavica 1991 84 3 177 180 2-s2.0-0025733536
44. Nakamura K., Hirai H., Torashima T., CD3 and immunoglobulin G Fc receptor regulate cerebellar functions. Molecular and Cellular Biology 2007 27 14 5128 5134 2-s2.0-34447520529 10.1128/MCB.01072-06 (Pubitemid 47068287)
45. Sedmak D. D., Davis D. H., Singh U., van de Winkel J. G. J., Anderson C. L., Expression of IgG Fc receptor antigens in placenta and on endothelial cells in humans. An immunohistochemical study. American Journal of Pathology 1991 138 1 175 181 2-s2.0-0026022295
46. Lyden T. W., Robinson J. M., Tridandapani S., The Fc receptor for IgG expressed in the villus endothelium of human placenta is Fc γ RIIb2. Journal of Immunology 2001 166 6 3882 3889 2-s2.0-0032937238 (Pubitemid 32224914)
47. Estienne V., Duthoit C., Reichert M., Androgen-dependent expression of Fc γ RIIB2 by thyrocytes from patients with autoimmune Graves' disease: a possible molecular clue for sex dependence of autoimmune disease. FASEB Journal 2002 16 9 1087 1092 2-s2.0-0036317991 10.1096/fj.01-0998hyp (Pubitemid 34753515)
48. Milgrom F., Humphrey L. J., Tönder O., Yasuda J., Witebsky E., Antibody-mediated hemadsorption by tumor tissues. International Archives of Allergy and Applied Immunology 1968 33 5 478 492 2-s2.0-0014243837
49. Tonder O., Thunold S., Receptors for immunoglobulin Fc in human malignant tissues. Scandinavian Journal of Immunology 1973 2 3 207 215 2-s2.0-0015852176
50. Witz I. P., The biological significance of tumor-bound immunoglobulins. Current Topics in Microbiology and Immunology 1973 61 151 171 2-s2.0-0015551066
51. Biran H., Mavligit G. M., Moake J. L., Receptor sites for complement and for immune complexes on human nonhemopoietic tumor cells. Cancer 1979 44 1 131 135 2-s2.0-0018763559 (Pubitemid 9234922)
52. Noltenius H. W., Fc and complement receptors on malignant tumor cells. Cancer 1981 48 8 1761 1767 2-s2.0-0019453729 (Pubitemid 11022878)
53. Braslawsky G. R., Yaackubowicz M., Frensdorff A., Witz I. P., Receptors for immune complexes on cells within a non lymphoid murine tumor. Journal of Immunology 1976 116 6 1571 1578 2-s2.0-0017174725
54. Svennevig J.-L., Andersson T. R., Cells bearing Fc receptors in human malignant solid tumours. British Journal of Cancer 1982 45 2 201 208 2-s2.0-0020084282 (Pubitemid 12177669)
55. Ran M., Teillaud J.-L., Fridman W. H., Increased expression of Fc γ receptor in cancer patients and tumor bearing mice. Molecular Immunology 1988 25 11 1159 1167 2-s2.0-0023739284
56. Ran M., Katz B., Kimchi N., In vivo acquisition of Fc γ RII expression on polyoma virus-transformed cells derived from tumors of long latency. Cancer Research 1991 51 2 612 618 2-s2.0-0025957111
57. Szymaniec S., James K., Studies on the Fc receptor bearing cells in a transplanted methylcholanthrene induced mouse fibrosarcoma. British Journal of Cancer 1976 33 1 36 50 2-s2.0-0017283330
58. Gorini G., Ciotti M. T., Starace G., Vigneti E., Raschellà G., Fc gamma receptors are expressed on human neuroblastoma cell lines: lack of correlation with N-myc oncogene activity. International Journal of Neuroscience 1992 62 3-4 287 297 2-s2.0-0026816980
59. Cassard L., Cohen-Solal J. F. G., Galinha A.,. Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells. Journal of Clinical Investigation 2002 110 10 1549 1557 2-s2.0-0036854459 10.1172/JCI200215454 (Pubitemid 35402056)
60. Cassard L., Cohen-Solal J. F. G., Fournier E. M., Selective expression of inhibitory Fc γ receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. International Journal of Cancer 2008 123 12 2832 2839 2-s2.0-57349198014 10.1002/ijc.23870
61. Vedeler C. A., Scarpini E., Beretta S., Doronzo R., Matre R., The ontogenesis of Fc γ receptors and complement receptors CR1 in human peripheral nerve. Acta Neuropathologica 1990 80 1 35 40 2-s2.0-0025274775 (Pubitemid 20149992)
62. Neauport-Sautes C., Daëron M., Teillaud J. L., Blank U., Fridman W. H., The occurrence, structural and functional properties of immunoglobulin Fc receptors on murine neoplastic cells. International Reviews of Immunology 1986 1 3-4 237 271 2-s2.0-0022750464
63. Tridandapani S., Wang Y., Marsh C. B., Anderson C. L., Src homology 2 domain-containing inositol polyphosphate phosphatase regulates NF- B-mediated gene transcription by phagocytic Fc γ Rs in human myeloid cells. Journal of Immunology 2002 169 8 4370 4378 2-s2.0-0037108356 (Pubitemid 35178211)
64. Rothhammer T., Poser I., Soncin F., Bataille F., Moser M., Bosserhoff A.-K., Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Research 2005 65 2 448 456 2-s2.0-12544259720
65. Ran M., Langer A. B. B., Eliassi I., Possibilities of interference with the immune system of tumor bearers by non-lymphoid Fc γ RII expressing tumor cells. Immunobiology 1992 185 2-4 415 425
66. Zusman T., Gohar O., Eliassi I., The murine Fc- γ (Fc γ) receptor type II B1 is a tumorigenicity-enhancing factor in polyoma-virus- transformed 3T3 cells. International Journal of Cancer 1996 65 2 221 229 2-s2.0-9044225139 10.1002/(SICI)1097-0215(19960117)65:2<221::AID-IJC16>3. 0.CO;2-G (Pubitemid 26048917)
67. Zusman T., Lisansky E., Arons E., Contribution of the intracellular domain of murine FC-gamma receptor type IIB1 to its tumor-enhancing potential. International Journal of Cancer 1996 68 2 219 227 2-s2.0-0029823559 10.1002/(SICI)1097-0215(19961009)68:2<219::AID-IJC14>3.0.CO;2-5 (Pubitemid 26380127)
68. Yu D.-H., Qu C.-K., Henegariu O., Lu X., Feng G.-S., Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. Journal of Biological Chemistry 1998 273 33 21125 21131 2-s2.0-3543036342 10.1074/jbc.273.33.21125 (Pubitemid 28385400)
69. Wang F.-M., Liu H.-Q., Liu S.-R., Tang S.-P., Yang L., Feng G.-S., SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1 β in vivo and in vitro. Breast Cancer Research and Treatment 2005 89 1 5 14 2-s2.0-13644270390 10.1007/s10549-004-1002-z (Pubitemid 40228442)
70. Yo K., Iwata S., Hashizume Y., SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration. Biochemical and Biophysical Research Communications 2009 382 1 210 214 2-s2.0-63149148150 10.1016/j.bbrc.2009.03.010
71. Vijayasaradhi S., Bouchard B., Houghton A. N., The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. Journal of Experimental Medicine 1990 171 4 1375 1380 2-s2.0-0025317338 (Pubitemid 20120155)
72. Hara I., Takechi Y., Houghton A. N., Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. Journal of Experimental Medicine 1995 182 5 1609 1614 2-s2.0-0028786994 10.1084/jem.182.5.1609
73. Shibahara S., Okinaga S., Tomita Y., A point mutation in the tyrosinase gene of BALB/c albino mouse causing the cysteine-serine substitution at position 85. European Journal of Biochemistry 1990 189 2 455 461 2-s2.0-0025260987 (Pubitemid 20146033)
74. Takechi Y., Hara I., Naftzger C., Xu Y., Houghton A. N., A melanosomal membrane protein is a cell surface target for melanoma therapy. Clinical Cancer Research 1996 2 11 1837 1842 2-s2.0-0029852018 (Pubitemid 26384150)
75. Trcka J., Moroi Y., Clynes R. A., Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity 2002 16 6 861 868 2-s2.0-18444417703 10.1016/S1074-7613(02)00327-8 (Pubitemid 34786484)
76. van Spriel A. B., Leusen J. H. W., van Egmond M., Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. Blood 2001 97 8 2478 2486 2-s2.0-0035871884 10.1182/blood.V97.8.2478 (Pubitemid 32291496)
77. Thurin J., Thurin M., Kimoto Y., Monoclonal antibody-defined correlations in melanoma between levels of G(D2) and G(D3) antigens and antibody-mediated cytotoxicity. Cancer Research 1987 47 5 1229 1233 (Pubitemid 17023186)
78. Gross N., Beck D., Portoukalian J., Favre S., Carrel S., New anti-GD2 monoclonal antibodies produced from gamma-interferon-treated neuroblastoma cells. International Journal of Cancer 1989 43 4 665 671 2-s2.0-0024515820 (Pubitemid 19110103)
79. Saito N., Yu R. K., Cheung N. K. V., Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochemical and Biophysical Research Communications 1985 127 1 1 7 2-s2.0-0021955583 (Pubitemid 15146924)
80. Pearse R. N., Kawabe T., Bolland S., Guinamard R., Kurosaki T., Ravetch J. V., SHIP recruitment attenuates Fc γ RIIB-induced B cell apoptosis. Immunity 1999 10 6 753 760 2-s2.0-0033151596 10.1016/S1074-7613(00)80074-6 (Pubitemid 29302928)
81. Litvak D. A., Gupta R. K., Yee R., Wanek L. A., Ye W., Morton D. L., Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors. Journal of the American College of Surgeons 2004 198 1 27 35 2-s2.0-1042275877 10.1016/j.jamcollsurg.2003.08.012 (Pubitemid 38201085)
82. Gupta R. K., Leitch A. M., Morton D. L., Nature of antigens and antibodies in immune complexes isolated by staphylococcal protein A from plasma of melanoma patients. Cancer Immunology, Immunotherapy 1983 16 1 40 47 2-s2.0-0021062257 (Pubitemid 14246737)
83. Hsueh E. C., Gupta R. K., Qi K., Morton D. L., Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. Journal of Clinical Oncology 1998 16 9 2913 2920 2-s2.0-0031713904 (Pubitemid 28417409)
84. Strohl W. R., wstrohl@its.jnj.com Optimization of Fc-mediated effector functions of monoclonal antibodies. Current Opinion in Biotechnology 2009 20 6 685 691 2-s2.0-61849148375 10.1016/j.copbio.2009.10.011
85. Sibéril S., Dutertre C.-A., Fridman W.-H., Teillaud J.-L., Fc γ R: the key to optimize therapeutic antibodies? Critical Reviews in Oncology/Hematology 2007 62 1 26 33 2-s2.0-33847399072 10.1016/j.critrevonc. 2006.12.003 (Pubitemid 46343788)
86. Sibéril S., Dutertre C.-A., Boix C., Molecular aspects of human Fc γ R interactions with IgG: functional and therapeutic consequences. Immunology Letters 2006 106 2 111 118 2-s2.0-33747339717 10.1016/j.imlet.2006. 05.009
87. De Romeuf C., deromeuf@lfb.fr Dutertre C.-A., Le Garff-Tavernier M., Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of Fc γ RIIIA/CD16. British Journal of Haematology 2008 140 6 635 643 2-s2.0-39749086517 10.1111/j.1365-2141.2007.06974.x (Pubitemid 351300917)
88. Veri M.-C., Gorlatov S., Li H., Monoclonal antibodies capable of discriminating the human inhibitory Fc γ -receptor IIB (CD32B) from the activating Fc γ -receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 2007 121 3 392 404 2-s2.0-34249341152 10.1111/j.1365-2567.2007.02588.x (Pubitemid 46817361)
89. Rankin C. T., Veri M.-C., Gorlatov S., CD32B, the human inhibitory Fc- γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 2006 108 7 2384 2391 2-s2.0-33749368008 10.1182/blood-2006-05- 020602 (Pubitemid 44497523)
90. Shah S., Divekar A. A., Hilchey S. P., Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and T1 cytokine responses by B cells. International Journal of Cancer 2005 117 4 574 586 2-s2.0-27144471717 10.1002/ijc.21177 (Pubitemid 41504545)
91. Dilillo D. J., Yanaba K., Tedder T. F., B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. Journal of Immunology 2010 184 4006 4016
92. Polak M. E., Borthwick N. J., Gabriel F. G., Mechanisms of local immunosuppression in cutaneous melanoma. British Journal of Cancer 2007 96 12 1879 1887 2-s2.0-34250360586 10.1038/sj.bjc.6603763 (Pubitemid 46912012)
93. Tridandapani S., tridandapani.@osu.edu Wardrop R., Baran C. P., TGF- β 1 supresses myeloid Fc γ receptor function by regulating the expression and function of the common γ -subunit. Journal of Immunology 2003 170 9 4572 4577 2-s2.0-0031065139 (Pubitemid 36519963)
94. Joshi T., Ganesan L. P., Cao X., Tridandapani S., Molecular analysis of expression and function of hFc γ RIIbl and b2 isoforms in myeloid cells. Molecular Immunology 2006 43 7 839 850 2-s2.0-29144443587 10.1016/j.molimm.2005. 06.037 (Pubitemid 41814401)
95. Trotta R., Col J. D., Yu J., TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. Journal of Immunology 2008 181 6 3784 3792 2-s2.0-56149090590